SB-201076

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555907

CAS#: 154566-05-9

Description: SB-201076 is a potent ATP citrate-lyase inhibitor. SB-204990 is the prodrug of SB-201076.


Chemical Structure

img
SB-201076
CAS# 154566-05-9

Theoretical Analysis

MedKoo Cat#: 555907
Name: SB-201076
CAS#: 154566-05-9
Chemical Formula: C18H24Cl2O6
Exact Mass: 406.10
Molecular Weight: 407.284
Elemental Analysis: C, 53.08; H, 5.94; Cl, 17.41; O, 23.57

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SB-201076; SB 201076; SB201076;

IUPAC/Chemical Name: (S)-(3R*,5S*)-3-Carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic Acid

InChi Key: NPZOIISFQXTCQN-KDOFPFPSSA-N

InChi Code: InChI=1S/C18H24Cl2O6/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14(21)10-18(26,17(24)25)11-16(22)23/h7-9,14,21,26H,1-6,10-11H2,(H,22,23)(H,24,25)/t14-,18+/m1/s1

SMILES Code: O=C(O)C[C@](O)(C(O)=O)C[C@H](O)CCCCCCC1=CC=C(Cl)C=C1Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 407.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sanfilippo J, Ness M, Petscher Y, Rappaport L, Zuckerman B, Gaab N. Reintroducing Dyslexia: Early Identification and Implications for Pediatric Practice. Pediatrics. 2020 Jul;146(1):e20193046. doi: 10.1542/peds.2019-3046. Epub 2020 Jun 23. PMID: 32576595; PMCID: PMC7329249.


2: Feng X, Zhang L, Xu S, Shen AZ. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Prog Lipid Res. 2020 Jan;77:101006. doi: 10.1016/j.plipres.2019.101006. Epub 2019 Sep 6. PMID: 31499095.


3: Birchenall KA, Welsh GI, López Bernal A. Metabolite Changes in Maternal and Fetal Plasma Following Spontaneous Labour at Term in Humans Using Untargeted Metabolomics Analysis: A Pilot Study. Int J Environ Res Public Health. 2019 Apr 30;16(9):1527. doi: 10.3390/ijerph16091527. PMID: 31052173; PMCID: PMC6539865.


4: Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, Li J, Zhu J, Shen Z, Haffty BG, Hu W, Feng Z. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116. PMID: 27664236; PMCID: PMC5066239.


5: Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol. 2015 Apr;19(2):298-308. doi: 10.1007/s10157-014-0976-z. Epub 2014 May 4. PMID: 24792810.


6: Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD. ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells. J Biol Chem. 2010 Oct 15;285(42):32606-15. doi: 10.1074/jbc.M110.157172. Epub 2010 Aug 7. PMID: 20693577; PMCID: PMC2952263.


7: Yang L, Wang DX, Zheng QY, Pan J, Huang ZT, Wang MX. Highly efficient and concise synthesis of both antipodes of SB204900, clausenamide, neoclausenamide, homoclausenamide and zeta-clausenamide. Implication of biosynthetic pathways of Clausena alkaloids. Org Biomol Chem. 2009 Jun 21;7(12):2628-34. doi: 10.1039/b901965k. Epub 2009 May 5. PMID: 19503939.


8: Yoo B. Impact of missing data on type 1 error rates in non-inferiority trials. Pharm Stat. 2010 Apr-Jun;9(2):87-99. doi: 10.1002/pst.378. PMID: 19408241.


9: Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005 Oct;8(4):311-21. doi: 10.1016/j.ccr.2005.09.008. PMID: 16226706.


10: Michno A, Skibowska A, Raszeja-Specht A, Cwikowska J, Szutowicz A. The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus. Metabolism. 2004 Jan;53(1):66-72. doi: 10.1016/j.metabol.2003.07.012. PMID: 14681844.


11: Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, Camilleri P, Sweeney P, Gribble AD, Shaw A, Groot PH. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):113-9. doi: 10.1042/bj3340113. PMID: 9693110; PMCID: PMC1219669.


12: van Vlijmen BJ, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PH. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung. 1998 Apr;48(4):396-402. PMID: 9608883.